Compliance Rate

Compliance Rate 50.0%
Compliant submissions 1
Incompliant submissions 1
Total trials 2

My Organizations' Clinical Trials

Showing 3025 of 3499 entries
View as:

Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Tamoxifen

Phase: N/A Priority: Normal
NCT ID: NCT00118157 Org: User:
Start: 05/31/05 End: 09/30/14 Due: 09/30/15

Phase I Study of Intensity Modulated Radiation Therapy for Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00124917 Org: User:
Start: 07/21/05 End: 05/09/17 Due: 05/09/18

Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

Phase: N/A Priority: Normal
NCT ID: NCT03213691 Org: User:
Start: 10/30/17 End: 12/31/24 Due: 12/31/25

Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy

Phase: N/A Priority: Normal
NCT ID: NCT06427798 Org: User:
Start: 02/07/25 End: 07/01/39 Due: 07/01/40

Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT04447027 Org: User:
Start: 12/17/20 End: 07/01/25 Due: 07/01/26

Decitabine in Treating Patients With Myelofibrosis

Phase: N/A Priority: Normal
NCT ID: NCT00095784 Org: User:
Start: 09/29/04 End: 02/22/26 Due: 02/22/27

Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)

Phase: N/A Priority: Normal
NCT ID: NCT03220035 Org: User:
Start: 11/08/17 End: 12/31/24 Due: 12/31/25

Testing Pembrolizumab Versus Observation in Patients With Merkel Cell Carcinoma After Surgery, STAMP Trial

Phase: N/A Priority: Normal
NCT ID: NCT03712605 Org: User:
Start: 11/15/18 End: 12/31/25 Due: 12/31/26

Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers

Phase: N/A Priority: Normal
NCT ID: NCT03816332 Org: User:
Start: 11/08/19 End: 09/22/25 Due: 09/22/26

Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

Phase: N/A Priority: Normal
NCT ID: NCT01258855 Org: User:
Start: 01/18/11 End: 03/29/18 Due: 03/29/19

Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04847466 Org: User:
Start: 12/14/21 End: 12/31/27 Due: 12/31/28

VB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC)

Phase: N/A Priority: Normal
NCT ID: NCT04166383 Org: User:
Start: 08/09/20 End: 12/31/22 Due: 12/31/23

LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Phase: N/A Priority: Normal
NCT ID: NCT04027946 Org: User:
Start: 09/11/19 End: 12/22/23 Due: 12/22/24

Rifaximin for Chronic Immune Activation in People With HIV

Phase: N/A Priority: Normal
NCT ID: NCT01866826 Org: User:
Start: 01/18/13 End: 02/28/18 Due: 02/28/19

Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03348631 Org: User:
Start: 05/01/19 End: 02/12/26 Due: 02/12/27

Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers

Phase: N/A Priority: Normal
NCT ID: NCT03388632 Org: User:
Start: 02/05/18 End: 05/08/25 Due: 05/08/26

Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone

Phase: N/A Priority: Normal
NCT ID: NCT03660826 Org: User:
Start: 09/27/18 End: 01/24/26 Due: 01/24/27

Evaluation of Blood Vessel Formation in Endocrine Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00923780 Org: User:
Start: 01/05/07 End: - Due: -

RO4929097 in Treating Patients With Recurrent Invasive Gliomas

Phase: N/A Priority: Normal
NCT ID: NCT01269411 Org: User:
Start: 07/31/11 End: - Due: -

Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas

Phase: N/A Priority: Normal
NCT ID: NCT01514201 Org: User:
Start: 02/01/12 End: 03/28/18 Due: 03/28/19

Long-Term TARP Vaccination Using a Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Previously Vaccinated Men on NCI 09-C-0139

Phase: N/A Priority: Normal
NCT ID: NCT02362464 Org: User:
Start: 05/12/15 End: 03/25/22 Due: 03/25/23

SU5416 and Irinotecan in Treating Patients With Advanced Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00005818 Org: User:
Start: 03/31/00 End: - Due: -

Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT01238146 Org: User:
Start: 10/31/10 End: - Due: -

Azacitidine and Oxaliplatin In Treating Patients With Advanced Cancers Relapsed or Refractory to Any Platinum Therapy

Phase: N/A Priority: Normal
NCT ID: NCT01039155 Org: User:
Start: 12/31/09 End: 07/31/15 Due: 07/31/16

Total Thyroidectomy With and Without Prophylactic Central Neck Lymph Node Dissection in People With Low-risk Papillary Thyroid Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02408887 Org: User:
Start: 04/15/15 End: 05/07/19 Due: 05/07/20